{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:10:29Z","timestamp":1771654229706,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coph.2021.07.003","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:40:30Z","timestamp":1629160830000},"page":"123-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Metabolic comorbidities of adrenal insufficiency: Focus on steroid replacement therapy and chronopharmacology"],"prefix":"10.1016","volume":"60","author":[{"given":"Valentina","family":"Guarnotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Amodei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-9395","authenticated-orcid":false,"given":"Carla","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.07.003_sref1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","article-title":"Adrenal insufficiency","volume":"397","author":"Husebye","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.07.003_sref2","doi-asserted-by":"crossref","first-page":"101379","DOI":"10.1016\/j.beem.2020.101379","article-title":"Autoimmune Addison's disease","volume":"34","author":"Saverino","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.coph.2021.07.003_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4158\/EP15754.OR","article-title":"Increasing prevalence of Addison disease: results from a nationwide study","volume":"22","author":"Olafsson","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.coph.2021.07.003_sref4","first-page":"dgab096","article-title":"Increased mortality risk in patients with primary and secondary adrenal insufficiency","volume":"17","author":"Ngaosuwan","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.coph.2021.07.003_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2013.09.007","article-title":"The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease","volume":"132","author":"Oakley","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2021.07.003_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4939-2895-8_5","article-title":"Regulation of glucose homeostasis by glucocorticoids","volume":"872","author":"Kuo","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coph.2021.07.003_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2265.1988.tb03673.x","article-title":"Glucocorticoids and glucose metabolism: hepatic glucose production in untreated Addisonian patients and on two different levels of glucocorticoid administration","volume":"28","author":"Malerbi","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.coph.2021.07.003_bib9","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1530\/JOE-14-0373","article-title":"Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes","volume":"223","author":"Rafacho","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib10","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","article-title":"The effects of glucocorticoids on adipose tissue lipid metabolism","volume":"60","author":"Peckett","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.coph.2021.07.003_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbadis.2013.05.029","article-title":"Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity","volume":"1842","author":"Lee","year":"2014","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"10.1016\/j.coph.2021.07.003_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1677\/JOE-08-0054","article-title":"Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome","volume":"197","author":"Macfarlane","year":"2008","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","article-title":"Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism","volume":"43","author":"Geer","year":"2014","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.coph.2021.07.003_bib14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1210\/me.2008-0464","article-title":"Direct effect of glucocorticoids on lipolysis in adipocytes","volume":"23","author":"Xu","year":"2009","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1172\/JCI116821","article-title":"Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men","volume":"92","author":"Fried","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2021.07.003_bib16","first-page":"820","article-title":"The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue","volume":"79","author":"Ottosson","year":"1994","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1152\/ajpcell.00045.2010","article-title":"Adipogenic and lipolytic effects of chronic glucocorticoid exposure","volume":"300","author":"Campbell","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.coph.2021.07.003_bib18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0026-0495(88)90009-1","article-title":"Effects of hormones on apolipoprotein secretion in cultured rat epatocytes","volume":"37","author":"Lin","year":"1988","journal-title":"Metabolism"},{"key":"10.1016\/j.coph.2021.07.003_bib19","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1210\/jc.2019-00420","article-title":"Glucocorticoid replacement affects serum adiponectin levels and HDL-C in patients with secondary adrenal insufficiency","volume":"104","author":"Hayashi","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/eci.12770","article-title":"Downregulation of cholesteryl ester transfer protein by glucocorticoids: a randomised study on HDL","volume":"47","author":"Werumeus Buning","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.coph.2021.07.003_bib21","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.2011-2813","article-title":"Impact of mifepristone, a glucocorticoid\/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function","volume":"97","author":"Page","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib22","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jcem-67-6-1122","article-title":"Muscle and adipose tissue morphology and metabolism in Cushing's syndrome","volume":"67","author":"Rebuffe-Scrive","year":"1988","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.addr.2019.02.004","article-title":"Chronopharmacology of glucocorticoids","volume":"151","author":"Scherholz","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.coph.2021.07.003_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.coph.2021.07.003_bib25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/BF03345773","article-title":"Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement","volume":"32","author":"Giordano","year":"2009","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.coph.2021.07.003_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijcard.2015.03.034","article-title":"Cardiovascular risk factors and disease in patients with hypothalamic pituitary disorders","volume":"184","author":"Harbeck","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.coph.2021.07.003_bib27","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1210\/jc.2017-01324","article-title":"Visceral fat and novel biomarkers of cardiovascular disease in patients with addison's disease: a case-control study","volume":"102","author":"Bergthorsdottir","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.coph.2021.07.003_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-13-0754","article-title":"Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?","volume":"170","author":"Giordano","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12020-016-0914-9","article-title":"The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome","volume":"55","author":"Guarnotta","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.coph.2021.07.003_bib30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib31","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcomeand comorbidity in hypopituitary patients","volume":"91","author":"Filipsson","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EC-16-0081","article-title":"EU-AIR Investigators: prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency","volume":"6","author":"Quinkler","year":"2017","journal-title":"Endocr Connect"},{"key":"10.1016\/j.coph.2021.07.003_bib33","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1530\/EC-17-0257","article-title":"Prednisolone has the same cardiovascular risk profile as hydrocortisone in glucocorticoid replacement","volume":"6","author":"Smith","year":"2017","journal-title":"Endocr Connect"},{"key":"10.1016\/j.coph.2021.07.003_sref34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12020-019-02082-w","article-title":"Prednisolone or hydrocortisone replacement in patients with corticotrope deficiency fasting during Ramadan result in similar risks of complications and quality of life: a randomized double-blind controlled trial","volume":"67","author":"Chihaoui","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.coph.2021.07.003_sref35","doi-asserted-by":"crossref","first-page":"bvaa160","DOI":"10.1210\/jendso\/bvaa160","article-title":"Metabolic effects of cortisone acetate vs hydrocortisone in patients with secondary adrenal insufficiency","volume":"4","author":"Ekstrand","year":"2020","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.coph.2021.07.003_sref36","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1210\/jc.2018-02298","article-title":"Sex-specific risk of cardiovascular disease in autoimmune addison disease-A population-based cohort study","volume":"104","author":"Skov","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib37","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1530\/EJE-17-0154","article-title":"Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects","volume":"177","author":"Mazziotti","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_sref38","first-page":"1","article-title":"Glucocorticoid excess and COVID-19 disease","volume":"6","author":"Guarnotta","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.coph.2021.07.003_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2265.1995.tb02928.x","article-title":"Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism","volume":"43","author":"Dunne","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.coph.2021.07.003_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11102-008-0126-2","article-title":"Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study","volume":"11","author":"Danilowicz","year":"2008","journal-title":"Pituitary"},{"key":"10.1016\/j.coph.2021.07.003_bib41","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1210\/jc.2013-4305","article-title":"Acute effect of increasing glucocorticoid replacement dose on cardiovascular risk and insulin sensitivity in patients with adrenocorticotrophin deficiency","volume":"99","author":"Petersons","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.coph.2021.07.003_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ando.2014.11.004","article-title":"An observational study on adrenal insufficiency in a French tertiary centre: real life versus theory","volume":"76","author":"Castinetti","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.coph.2021.07.003_bib43","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1530\/EJE-15-1187","article-title":"Low-dose hydrocortisone replacement is associated with improved arterial stiffness index and blood pressure dynamics in severely adrenocorticotrophin-deficient hypopituitary male patients","volume":"174","author":"Behan","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.0300-0664.2001.01447.x","article-title":"Effects of low-dose oral hydrocortisone replacement versus short-term reproduction of physiological serum cortisol concentrations on insulin action in adult-onset hypopituitarism","volume":"56","author":"McConnell","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/EJE-09-0170","article-title":"Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study","volume":"161","author":"Johannsson","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","author":"Johannsson","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/EJE-14-1114","article-title":"Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency","volume":"172","author":"Quinkler","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12020-015-0681-z","article-title":"Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease","volume":"51","author":"Giordano","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.coph.2021.07.003_bib49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/EJE-17-0067","article-title":"Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study","volume":"176","author":"Nilsson","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","article-title":"Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial","volume":"6","author":"Isidori","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EC-17-0368","article-title":"Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life","volume":"7","author":"Mongio\u00ec","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.coph.2021.07.003_bib52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12020-017-1512-1","article-title":"Bone safety of dual-release hydro-cortisone in patients with hypopituitarism","volume":"60","author":"Frara","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.coph.2021.07.003_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-018-1628-y","article-title":"Multiple benefits from dual release hydrocortisone: a \u201chard\u201d view from bones","volume":"61","author":"Vassiliadi","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.coph.2021.07.003_bib54","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1530\/EC-18-0257","article-title":"Improved salivary cortisol rhythm with dual-release hydrocortisone","volume":"7","author":"Ceccato","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.coph.2021.07.003_bib55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/cen.13554","article-title":"Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis","volume":"88","author":"Guarnotta","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.coph.2021.07.003_sref56","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1530\/EC-19-0176","article-title":"Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency","volume":"8","author":"Guarnotta","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.coph.2021.07.003_sref57","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819871169","article-title":"Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study","volume":"10","author":"Guarnotta","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_sref58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/cen.14275","article-title":"Systematic review and meta-analysis of the metabolic effects of modified-release hydrocortisone versus standard glucocorticoid replacement therapy in adults with adrenal insufficiency","volume":"93","author":"Bannon","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.coph.2021.07.003_bib59","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-18-0102","article-title":"Mechanisms in endocrinology: a sense of time of the glucocorticoid circadian clock: from the ontogeny to the diagnosis of Cushing's syndrome","volume":"179","author":"Moreira","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib60","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1210\/js.2018-00021","article-title":"Multimodal regulation of circadian glucocorticoid rhythm by central and adrenal clocks","volume":"2","author":"Son","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.coph.2021.07.003_sref61","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/JOE-20-0066","article-title":"Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy","volume":"246","author":"Minnetti","year":"2020","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.coph.2021.07.003_bib62","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1126\/science.289.5488.2344","article-title":"Resetting of circadian time in peripheral tissues by glucocorticoid signaling","volume":"289","author":"Balsalobre","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.coph.2021.07.003_sref63","first-page":"dgab347","article-title":"Full Mortality risk in patients with adrenal insufficiency using Prednisolone or Hydrocortisone: a Retrospective Cohort study","author":"Ngaosuwan","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_bib64","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1210\/jc.2018-00346","article-title":"Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a dream trial ancillary study","volume":"103","author":"Venneri","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.003_sref65","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-020-02578-w","article-title":"Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone","volume":"73","author":"Pilli","year":"2021","journal-title":"Endocrine"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:56:42Z","timestamp":1761461802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221000965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":65,"alternative-id":["S1471489221000965"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.07.003","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic comorbidities of adrenal insufficiency: Focus on steroid replacement therapy and chronopharmacology","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}